Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study.
Authors
Antoine Hollebecque
Gustave Roussy, Villejuif, France
Antoine Hollebecque , Yasutoshi Kuboki , Yonina R. Murciano-Goroff , Rona Yaeger , Philippe Alexandre Cassier , Rebecca Suk Heist , Yutaka Fujiwara , Dustin A. Deming , Natraj Ammakkanavar , Amita Patnaik , Toshio Shimizu , Justin Call , Sae-Won Han , Aaron Alan Fink , Aaron Chen , Melinda D Willard , Arjun Vasant Balar , Takafumi Koyama
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04956640
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 94)
DOI
10.1200/JCO.2024.42.3_suppl.94
Abstract #
94
Poster Bd #
F17
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Interim safety and efficacy results from a phase 1 study of NT219 in adults with advanced solid tumors.
First Author: Alberto Bessudo
Poster
2024 ASCO Annual Meeting
Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.
First Author: Susanna Varkey Ulahannan
Poster
2023 ASCO Annual Meeting
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.
First Author: Dan-yun Ruan
Poster
2023 ASCO Annual Meeting
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
First Author: Maria Pia Morelli